Evidence map›Paper›PMID 40510466›Full record

ReviewFrontiers in endocrinology2025

A review of adipose-derived mesenchymal stem cells' impacts and challenges: metabolic regulation, tumor modulation, immunomodulation, regenerative medicine and genetic engineering therapies.

Lihong Wang, Xiaorui Jiang, Fen Zhao, Ping Duan, Zhengguang Li, Yiqiao Luo

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lihong WangChengdu Integrated TCM and Western Medical Hospital, Department of Oncology, Chengdu, Sichuan, China.
Xiaorui JiangChengdu Integrated TCM and Western Medical Hospital, Department of Oncology, Chengdu, Sichuan, China.
Fen ZhaoChengdu Integrated TCM and Western Medical Hospital, Department of Oncology, Chengdu, Sichuan, China.
Ping DuanChengdu Integrated TCM and Western Medical Hospital, Department of Oncology, Chengdu, Sichuan, China.
Zhengguang LiChengdu Integrated TCM and Western Medical Hospital, Department of Oncology, Chengdu, Sichuan, China.
Yiqiao LuoCancer Center, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adipose-derived mesenchymal stem cells (ADSCs), multipotent stromal cells abundant in adipose tissue, exhibit remarkable plasticity in modulating systemic metabolism, inflammatory responses, and immune homeostasis. Their bidirectional interactions with the tumor microenvironment (TME) position them as both accomplices and antagonists in cancer progression, offering unique therapeutic opportunities. ADSCs also hold significant potential for clinical application in the fields of regenerative medicine, tissue engineering, and gene engineering. This review synthesizes the impacts and challenges of ADSCs involving metabolic regulation, tumor modulation, immunomodulation, regenerative medicine and genetic engineering therapies-while elucidating underlying molecular mechanisms and signaling pathways, clinical studies, applications and challenges.

Indexed as

Adipose TissueGenetic EngineeringGenetic TherapyImmunomodulationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeoplasmsRegenerative MedicineAnimalsHumansTissue EngineeringTumor Microenvironmentadipose-derived mesenchymal stem cells (ADSCs)drug delivery systemsimmunomodulationmetabolic regulationmetabolic syndrometumor microenvironment (TME)

Identifiers

PMID40510466
PMCPMC12158724

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.